Drug intelligence / Profile preview

TQ-1002

Development stage: Preclinical
Lead developer: TQ Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies

Overview

TQ-1002 is an experimental *in vivo* chimeric antigen receptor (CAR) T-cell therapy being developed by TQ Therapeutics for the treatment of infectious diseases. The therapy utilizes TQ Therapeutics' proprietary EXiVO platform, which is designed to deliver genetic material directly to T cells within the patient's body, thereby generating CAR-T cells *in situ*. This approach aims to overcome the logistical and manufacturing challenges associated with traditional *ex vivo* CAR-T therapies. While the specific molecular target and the particular infectious disease indication have not been disclosed, TQ-1002 is intended to leverage the immune system to identify and clear pathogens or infected cells. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on TQ-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-1002.

Explore the full profile